기저세포암 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료 유형별, 지역별, 부문별 예측(2024-2030년)

Basal Cell Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment Type, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,590,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,034,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,922,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

기저세포암 치료 시장 성장과 동향

Grand View Research의 최신 보고서에 따르면, 세계 기저세포암 치료 시장 규모는 2030년까지 59억 3,000만 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 10.44%의 성장률을 보일 것으로 전망됩니다.

이 시장은 주로 기저세포암의 유병률 증가와 노령 인구의 증가가 주도하고 있습니다. 유럽 피부암 재단의 추정에 따르면 기저세포암(BCC) 발생률은 유럽에서 인구 10만 명당 연간 50-80명, 호주에서 인구 10만 명당 연간 250명이 새로 발생하며 증가 추세에 있습니다. 암 환자 수의 증가는 주로 전체 인구와 노인 인구의 증가와 특정 사회 경제적 요인에 기인합니다.

질병 진단 및 치료 기술의 발전은 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다. 첨단 기술을 통해 피부과 의사는 환자를 보다 정확하게 진단하고 기저세포암을 다른 피부 병변과 효과적으로 구별할 수 있습니다. 예를 들어, 2024년 미국 FDA는 흑색종, 단세포암(SCC), 기저세포암(BCC)을 포함한 피부암을 검출하는 AI 기반 광분광기 DermaSensor를 승인했습니다. 이 기술은 일차 진료 임상의가 생검이나 전문의의 치료가 필요한 환자를 신속하게 식별하여 대기 시간 및 특정 지역의 피부과 전문의 부족을 완화하는 데 도움이 될 수 있습니다. 이러한 진단 도구의 사용 증가는 향후 진단 및 치료율을 향상시켜 기저세포암 치료에 사용되는 의약품의 수요를 견인할 것으로 예상됩니다.

또한 노인 인구의 증가는 수술, 방사선 치료, 국소 화학 요법, 약물 치료, 화학적 필링과 같은 BCC 치료에 대한 수요를 주도하고 있으며, BCC 발병의 주요 원인은 자외선(UV)에 반복적으로 노출되는 것입니다. 노인은 자외선에 노출되는 시간이 길기 때문에 젊은 사람보다 BCC에 걸릴 확률이 높습니다. 노화와 면역 기능 저하로 인해 자외선 및 기타 발암 인자가 DNA를 더 쉽게 파괴하기 때문에 노인은 피부암, 특히 BCC의 위험이 증가하며, 2023년 Journal of Geriatric Oncology 저널에 발표된 연구에 따르면 미국에서 매년 10만 명 이상의 BCC 환자들은 인생의 마지막 해에 치료를 받고 있습니다. 따라서 노인 인구의 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

기저세포암 치료 보고서 하이라이트

• 2023년 시장에서 가장 큰 매출 점유율을 차지한 것은 수술 부문이었습니다. 이는 질병의 이환율과 유병률의 증가와 높은 안전성과 효과로 인해 치료를 위한 수술에 대한 수요가 높기 때문입니다.
• 국소 화학 요법에서 5-플루오로우라실(5-FU) 부문은 2023년 시장에서 가장 큰 점유율을 차지했습니다. 이는 BCC 환자를 치료하기 위한 5-플루오로우라실(5-FU)의 새로운 제네릭 버전의 개발 및 출시에 기인합니다.
• 북미는 선진화된 의료 인프라, 기저세포암 유병률 증가, 신제품 연구개발에 유리한 규제 환경 등의 요인으로 인해 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 기저세포암 치료 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• 기저세포암 치료 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 기저세포암 치료 시장 : 치료 유형 추정·동향 분석

• 세계의 기저세포암 치료 시장 : 치료 유형 대시보드
• 세계의 기저세포암 치료 시장 : 치료 유형 변동 분석
• 세계의 기저세포암 치료 시장 : 치료 유형별, 매출별
• 수술
• 방사선 치료(RT)
• 병변내 주사
• 국소 화학요법
• 경구제
• 정맥내 투여약
• 케미컬 필링 치료

제5장 기저세포암 치료 시장 : 치료 유형별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제6장 경쟁 상황

• 기업/경쟁 분류
• 진출 기업 개요
• 재무 개요
• 치료 유형 벤치마크
• 기업 시장 점유율 분석, 2023년
• 전략 매핑
• 기업 개요
  • Bausch Health Companies Inc.
  • Almirall, SA
  • Genentech, Inc.(Subsidiary of F. Hoffmann-La Roche AG)
  • Novartis AG.
  • Regeneron Pharmaceuticals Inc.
  • Dr Reddy's Laboratories.
  • Taro Pharmaceuticals Ltd.
  • Accord Healthcare Limited(Subsidiary of Intas Pharmaceuticals)

ksm

영문 목차

영문목차

Basal Cell Carcinoma Treatment Market Growth & Trends:

The global basal cell carcinoma treatment market size is anticipated to reach USD 5.93 billion by 2030, growing at a CAGR of 10.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of basal cell carcinoma and the rising geriatric population. The European Skin Cancer Foundation estimates that the incidence of basal cell carcinoma (BCC) is 50 to 80 new cases per 100,000 people in Europe and 250 cases per 100,000 people in Australia annually, with an increasing trend. The increase in the number of cancer cases can primarily be attributed to the growing overall & geriatric population and certain socioeconomic factors.

Technological advancement in the diagnosis and treatment of disease is anticipated to positively impact market growth. With advanced technologies, dermatologists can more accurately diagnose patients and effectively differentiate basal cell carcinoma from other skin lesions. For instance, in 2024, the U.S. FDA approved DermaSensor, an AI-powered light spectroscopy instrument for detecting skin cancer, including melanoma, single cell carcinoma (SCC), and basal cell carcinoma (BCC). This technique can help primary care clinicians identify patients who require rapid attention for a biopsy and specialist care, thereby alleviating high wait times and the shortage of dermatologists in certain places. The growing use of such diagnostic tools is expected to increase the diagnostic and treatment rates in the future, driving demand for medicines used for the treatment of basal cell carcinoma.

Furthermore, the increase in the geriatric population is driving the demand for treatment of BCC, including surgery, radiotherapy, topical chemotherapy, oral medications, and chemical peeling. The main cause of developing BCC is repeated exposure to Ultraviolet (UV) light. The elderly population has a higher chance of acquiring BCC than younger people as they have been exposed to UV rays for longer during their lifetime. Due to aging and reduced immune system function, UV radiation and other carcinogenic factors can break the DNA more easily, increasing the risk of skin cancer, especially BCC, in older persons. According to a study published in the Journal of Geriatric Oncology in 2023, over 100,000 patients with BCC are treated annually in their final year of life in the U.S. However, clinical practice guidelines hardly ever take age & comorbidities into account. Thus, a growing geriatric population is expected to drive market growth during the forecast period.

Basal Cell Carcinoma Treatment Report Highlights:

• The surgery segment held the largest revenue share of the market in 2023. This can be attributed to the increasing incidence and prevalence of disease and the high demand for surgery for treatment owing to high safety and efficacy.
• In topical chemotherapy, the 5-fluorouracil (5-FU) segment held the largest share of the market in 2023. This can be attributed to the development and launch of a novel generic version of 5-fluorouracil (5-FU) to treat BCC patients.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, increasing prevalence of basal cell carcinoma, and favorable regulatory environment for R&D of novel products.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment Type
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Type Outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Basal Cell Carcinoma Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of target diseases
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Rising geriatric population
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Adverse effects associated with treatment.
    • 3.2.2.2. High cost of treatment
• 3.3. Basal Cell Carcinoma Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Basal Cell Carcinoma Treatment Market: Treatment Type Estimates & Trend Analysis

• 4.1. Global Basal Cell Carcinoma Treatment Market: Treatment Type Dashboard
• 4.2. Global Basal Cell Carcinoma Treatment Market: Treatment Type Movement Analysis
• 4.3. Global Basal Cell Carcinoma Treatment Market By Treatment Type, Revenue
• 4.4. Surgery
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Mohs Surgery
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Surgical Excision
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Electrodesiccation and Curettage (ED&C)
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Radiotherapy (RT)
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Intralesional Injections
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Topical Chemotherapy
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.2. 5-fluorouracil (5-FU)
    • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.3. Tirbanibulin (Klisyri)
    • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7.4. Imiquimod (Zyclara)
    • 4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Oral Medications
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.2. Vismodegib (Erivedge)
    • 4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8.3. Sonidegib (Odomzo)
    • 4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Intravenous Medications
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Chemical Peeling Treatment
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million).

Chapter 5. Basal Cell Carcinoma Treatment Market: Regional Estimates & Trend Analysis By Treatment Type

• 5.1. Regional Dashboard
• 5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.3. North America
  • 5.3.1. U.S.
    • 5.3.1.1. Key country dynamics
    • 5.3.1.2. Regulatory framework/ reimbursement structure
    • 5.3.1.3. Competitive scenario
    • 5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.2. Canada
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Regulatory framework/ reimbursement structure
    • 5.3.2.3. Competitive scenario
    • 5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.3. Mexico
    • 5.3.3.1. Key country dynamics
    • 5.3.3.2. Regulatory framework/ reimbursement structure
    • 5.3.3.3. Competitive scenario
    • 5.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. UK
    • 5.4.1.1. Key country dynamics
    • 5.4.1.2. Regulatory framework/ reimbursement structure
    • 5.4.1.3. Competitive scenario
    • 5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Germany
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. France
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Italy
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework/ reimbursement structure
    • 5.4.4.3. Competitive scenario
    • 5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Spain
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Regulatory framework/ reimbursement structure
    • 5.4.5.3. Competitive scenario
    • 5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Denmark
    • 5.4.6.1. Key country dynamics
    • 5.4.6.2. Regulatory framework/ reimbursement structure
    • 5.4.6.3. Competitive scenario
    • 5.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key country dynamics
    • 5.4.7.2. Regulatory framework/ reimbursement structure
    • 5.4.7.3. Competitive scenario
    • 5.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.8. Norway
    • 5.4.8.1. Key country dynamics
    • 5.4.8.2. Regulatory framework/ reimbursement structure
    • 5.4.8.3. Competitive scenario
    • 5.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Japan
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. India
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Australia
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. South Korea
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Latin America
  • 5.6.1. Brazil
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Argentina
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. MEA
  • 5.7.1. South Africa
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Saudi Arabia
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. UAE
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.4. Kuwait
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Company/Competition Categorization
• 6.2. Participant Overview
• 6.3. Financial Overview
• 6.4. Treatment Type Benchmarking
• 6.5. Company Market Share Analysis, 2023
• 6.6. Strategy Mapping
• 6.7. Company Profiles
  • 6.7.1. Bausch Health Companies Inc.
    • 6.7.1.1. Company overview
    • 6.7.1.2. Financial performance
    • 6.7.1.3. Product benchmarking
    • 6.7.1.4. Strategic initiatives
  • 6.7.2. Almirall, S.A.
    • 6.7.2.1. Company overview
    • 6.7.2.2. Financial performance
    • 6.7.2.3. Product benchmarking
    • 6.7.2.4. Strategic initiatives
  • 6.7.3. Genentech, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
    • 6.7.3.1. Company overview
    • 6.7.3.2. Financial performance
    • 6.7.3.3. Product benchmarking
    • 6.7.3.4. Strategic initiatives
  • 6.7.4. Novartis AG.
    • 6.7.4.1. Company overview
    • 6.7.4.2. Financial performance
    • 6.7.4.3. Product benchmarking
    • 6.7.4.4. Strategic initiatives
  • 6.7.5. Regeneron Pharmaceuticals Inc.
    • 6.7.5.1. Company overview
    • 6.7.5.2. Financial performance
    • 6.7.5.3. Product benchmarking
    • 6.7.5.4. Strategic initiatives
  • 6.7.6. Dr Reddy's Laboratories.
    • 6.7.6.1. Company overview
    • 6.7.6.2. Financial performance
    • 6.7.6.3. Product benchmarking
    • 6.7.6.4. Strategic initiatives
  • 6.7.7. Taro Pharmaceuticals Ltd.
    • 6.7.7.1. Company overview
    • 6.7.7.2. Financial performance
    • 6.7.7.3. Product benchmarking
    • 6.7.7.4. Strategic initiatives
  • 6.7.8. Accord Healthcare Limited (Subsidiary of Intas Pharmaceuticals)
    • 6.7.8.1. Company overview
    • 6.7.8.2. Financial performance
    • 6.7.8.3. Product benchmarking
    • 6.7.8.4. Strategic initiatives

관련자료